Conference Proceeding

Intra-operative cell salvage use in ovarian cancer surgery

Dr. KhadraGalaal,
Consultant, MPH, FRCOG, UK

Dr. Khadra Galaal qualified in medicine from Dundee University in 1992 and after specialty training in Obstetrics and Gynecology, with subspecialty training in Gynaecological Oncology at the Queen Elizabeth Hospital, Gates head. Later she moved to Royal Cornwall hospital in Truro where she was appointed as consultant gynaecological oncologist the lead of the gynaecological cancer services. In December 2015 she was appointed as the chair of the Peninsula NSSG.

Intraoperative cell salvage (IOCS) involves the separation, centrifugation, washing and reinfusion into the patient’s blood. The use of IOCS reduces dependence on the limited pool of banked blood, is immediately available in theatreand avoids the biological issues that occur with deterioration of stored blood products, such as oxidative damage. Several studies in oncology surgery have suggested that the use of conventional blood transfusion is associated with higher rates of cancer recurrence, increased postoperative infection and alloimmunisation compared to IOCS. However, intraoperative cell salvage remains controversial in gynecological cancer surgery, in part because of the theoretical risk of disseminating malignant tumor cells into a patient’s bloodstream. However, so far there are no studies substantiating poorer survival out comes in ovarian cancer with IOCS.

Published: 11 May 2017